Into the Future of Dementia-Related Psychosis Care: Accurate Diagnosis and Safe Treatment (CME/CE Webcast)
Activity Description and Purpose
The prevalence of dementias is increasing rapidly in the United States and consequently so is the burden of associated neuropsychiatric symptoms. Dementia-related psychosis (DRP) can be particularly challenging and is associated with earlier institutionalization, lower quality of life, and accelerated mortality among affected patients. In this CME/CE webcast, renowned experts will discuss current best practices for assessment, diagnosis, and management of DRP as well as pertinent clinical trials for off-label and emerging antipsychotics used to treat DRP. The desired results of this activity are for physicians, physician assistants, nurses, social workers, and psychologists to confidently diagnose DRP and treat symptoms effectively while maintaining safety and quality of life of patients.
This educational activity is intended for psychiatrists, physician assistants, nurses, social workers, and psychologists caring for patients with dementia-related psychosis.
After completing this activity, participants will be better able to:
- Employ best practices in assessing symptoms of psychosis in patients with dementia
- Apply updated diagnostic criteria for dementia-related psychosis to various clinical scenarios
- Describe recent clinical trial data for the treatment of dementia-related psychosis
- Design evidence-based, safe treatment plans for persons with dementia-related psychosis
Marc E. Agronin, MD (Chair)
Senior Vice President for Behavioral Health
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
George T. Grossberg, MD
Samuel W. Fordyce Professor
Director, Geriatric Psychiatry
Department of Psychiatry and Behavioral Neuroscience
Saint Louis University School of Medicine
St Louis, Missouri
Pierre N. Tariot, MD
Director, Banner Alzheimer’s Institute
Research Professor of Psychiatry
University of Arizona College of Medicine
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Marc E. Agronin, MD, is a consultant for Eli Lilly and Company and Otsuka America Pharmaceutical, Inc; and is a contracted researcher for AgeneBio, Alzheon, Inc, Avanir Pharmaceuticals, Inc, Eli Lilly and Company, F. Hoffman La-Roche Ltd, Janssen Global Services, LLC, and Sage Therapeutics, Inc
George T. Grossberg, MD, is a consultant for ACADIA Pharmaceuticals Inc, Alkahest, Inc, Avanir Pharmaceuticals, Inc, Axovant Sciences Ltd, Axsome Therapeutics, Inc, Biogen Idec, BioXcel Therapeutics, F. Hoffman La-Roche Ltd, Genentech, Inc, H Lundbeck A/S, Karuna Therapeutics, Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical, Inc, and Takeda Pharmaceuticals USA, Inc; is a contracted researcher for F. Hoffman La-Roche Ltd, Genentech, Inc, Janssen Global Services, LLC, and NIA; is on the data monitoring committee of International Therapeutics, Inc; and is on the safety monitoring committee of Anavex Life Sciences Corp, EryDel SPA, Intra-Cellular Therapies Inc, Merck & Co., Inc, and Newron Pharmaceuticals SpA
Pierre N. Tariot, MD, is a consultant for AbbVie Inc, AC Immune SA, ACADIA Pharmaceuticals Inc, Biogen Idec, Genentech, Inc, Syneos Health, and T3D Therapeutics, Inc; and has individual stocks or stock options in Adamas Pharmaceuticals, Inc.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Physicians and Nurses:
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Association for Geriatric Psychiatry. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Successful completion of this program qualifies for up to 1.0 AMA PRA Category 1 Credit™ for physicians and 1.0 contact hour for nurses.
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. Social workers completing this course receive 1.0 continuing education credit.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, ACADIA Pharmaceuticals Inc, or FreeCME.
This CME/CE activity is copyrighted to MedEdicus LLC © 2021. All rights reserved. 245
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation